Ascendis Pharma A (ASND) Change in Account Payables (2014 - 2026)

Ascendis Pharma A (ASND) has 13 years of Change in Account Payables data on file, last reported at -$24.6 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Account Payables rose 42.53% year-over-year to -$24.6 million; the trailing twelve-month figure through Mar 2026 stood at -$26.9 million (down 540.89% YoY), and the FY2025 full-year result was -$49.2 million, down 268.68% from the prior year.
• Change in Account Payables fell to -$24.6 million in Q1 2026, from -$10.7 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $48.1 million in Q4 2024 to a low of -$42.9 million in Q1 2025.
• A 5-year average of $535476.0 and a median of -$4.9 million in 2022 frame the typical range for Change in Account Payables.
• Peak annual rise in Change in Account Payables reached 544.5% in 2024, while the deepest fall reached 275.44% in 2024.
• Tracing ASND's Change in Account Payables over 5 years: stood at $23.9 million in 2022, then slumped by 145.28% to -$10.8 million in 2023, then jumped by 544.5% to $48.1 million in 2024, then slumped by 122.28% to -$10.7 million in 2025, then slumped by 130.03% to -$24.6 million in 2026.
• Business Quant data shows ASND's Change in Account Payables at -$24.6 million in Q1 2026, -$10.7 million in Q4 2025, and -$8.8 million in Q3 2025.